Financial Data and Key Metrics Changes - For Q3 2025, total revenue was $196 million, an increase of approximately $1 million compared to the prior year [20] - Prescription transaction revenue decreased by 9% year-over-year, primarily due to the impact of Rite Aid store closures and lower transaction volume in the integrated savings program [21] - Adjusted EBITDA for the quarter was $66.3 million, reflecting a 2% increase year-over-year and an adjusted EBITDA margin of 33.8%, which is an improvement of 50 basis points compared to the prior year [22] Business Line Data and Key Metrics Changes - Manufacturer solutions revenue grew by 54% year-over-year to $43.4 million, driven by strong execution and expansion across new and existing brand partnerships [21][11] - The company has over 200 brand affordability programs on its platform, with nearly 80 offering cash prices [13] Market Data and Key Metrics Changes - The ongoing changes in the U.S. healthcare environment, particularly around prescription drug pricing, are seen as a significant opportunity for GoodRx, especially with the introduction of Trump Rx and the focus on price transparency [6][9] - The company is positioned to benefit from the anticipated increase in uninsured individuals and higher out-of-pocket costs due to changes in the Affordable Care Act marketplace subsidies and Medicaid support [9] Company Strategy and Development Direction - GoodRx is focused on expanding partnerships with pharmaceutical manufacturers and retail pharmacies to enhance access and affordability for consumers [19] - The company is investing in its manufacturer solutions capabilities and aims to deliver a true end-to-end e-commerce model to the pharmaceutical industry [14] - The new brand campaign, "The Savings Wrangler," aims to reinforce GoodRx's position as a trusted name in prescription savings and has already shown positive results in key marketing metrics [18] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the broader healthcare environment's challenges but remains confident in GoodRx's ability to navigate these changes and capitalize on emerging opportunities [10][25] - The company expects continued growth in its manufacturer solutions segment, projecting approximately 35% revenue growth in 2025 [24] - Management is optimistic about the long-term growth potential as the market shifts towards greater price transparency and consumer-direct models [9][26] Other Important Information - The company repurchased approximately 13.4 million shares at an average price of $4.61 per share, totaling $61.6 million, with about $81.4 million remaining under its share repurchase program [22] - GoodRx is actively engaged with the administration and HHS to inform policy efforts that expand access and affordability for all Americans [6] Q&A Session Summary Question: Can you discuss the stabilizing PTR environment and its implications for GoodRx? - Management noted that 2025 has been challenging due to various macro conditions but anticipates a return to growth in 2026 as more people may become uninsured, creating a tailwind for GoodRx [30][31] Question: How does GoodRx differentiate itself in the manufacturer solutions space? - GoodRx highlighted its position as the number one digital prescription marketplace, providing manufacturers with significant ROI and access to a large consumer base [33] Question: What are the implications of PBMs moving towards point-of-sale discounts? - Management expressed support for this shift, indicating that it aligns with GoodRx's mission of enhancing affordability for consumers at the pharmacy counter [36][37] Question: How will GoodRx integrate with Trump Rx? - GoodRx is actively working with HHS to integrate its pricing into the Trump Rx platform, positioning itself as a key provider of pricing information [39][41] Question: What is the outlook for the ISP relationship and potential new products? - Management indicated that while the ISP relationship has evolved, there remains potential for new product offerings that could enhance affordability for consumers [43][44]

Joining me now in an exclusive interview is Wayar CEO Matt Hawkins. His company is hosting its True North conference in Nashville this week to spotlight potential new AI solutions in healthcare software. Matt, welcome.Setting the table here a bit. It's interesting to me uh United Health, for example, has been having so much trouble lately in in part because of higher utilization uh and costs. I guess that's transactions and that that hunger for transactions is part of why you've been doing well.>> Well, we' ...

Core Insights - The article discusses various studies related to healthcare economics, focusing on cost transparency, mental health trends, and the impact of social factors on healthcare utilization and outcomes. Group 1: Healthcare Costs - The gradual disclosure of medical procedure prices on a government website led to a decrease in negotiated prices for surgical and radiology procedures by 5.1% and 9.1% respectively, primarily driven by provider-insurer negotiations rather than patient price shopping [9][11] - When primary care physicians (PCPs) are informed about specialist costs, referrals to lower-cost specialists increase by 4.6 percentage points for each rank reduction in costliness, potentially reducing referral costs by 45% in the short term [19][21] - A study on the Female Secondary School Stipend Program in Bangladesh found that it improved full immunization rates by 4.2 percentage points among children of mothers who received stipends for five years [39][40] Group 2: Mental Health - Worsening mental health has contributed to rising mortality rates among certain demographic groups, particularly non-Hispanic Whites, accounting for 9% to 29% of the increase in mortality rates [26][28][29] - Access to high-speed internet has been linked to increased mental health diagnoses and a rise in adolescent suicide rates, especially among girls [30][31] Group 3: Healthcare Demand - Non-clinical factors, such as living alone, significantly affect the length of hospital stays, particularly for elderly patients in public hospitals [36][37] - Rural populations exhibit a higher incidence of depression, with 33% to 39% of the rural-urban difference explained by factors such as income, education, and geographic region [33][34] Group 4: Neonatal Care - Advances in neonatal care have improved survival rates for high-risk newborns, but moderate-risk infants admitted to lower capability units received more intensive care, leading to reduced healthcare use post-discharge [16][18]